Artículos destacados sobre modelos y tecnologías de oncología

Vea un análisis exhaustivo de modelos tumorales preclínicos y tecnologías en estos artículos destacados de nuestros científicos.

A20: Modelos para linfoma de células B en ratones

Researchers are using preclinical mouse modeling in an effort to employ conventional treatment methods for lymphoma, such as radiotherapy and chemotherapy, in combination with immunomodulatory agents to more effectively treat this disease. Covance has developed the syngeneic A20 tumor model, a B cell lymphoma, to support these immuno-oncology applications.
Más información

A549: un modelo de cáncer de pulmón de células no pequeñas

Today a large number of human non-small cell lung cancer cell lines exist that are being used for both basic research and drug discovery. One commonly used line is A549, an epithelial carcinoma derived from a 58 year old male patient, known to be KRAS mutant and EGFR wild type.

Más información

CT26: carcinoma de colon murino

Preclinically, the murine CT26 colon carcinoma line has become a platform model for evaluating the potential of drug combinations with immune checkpoint inhibitor antibodies. It is a highly immunogenic tumor and tends to show objective response rates to a number of commercially available checkpoint inhibitors. At Covance, we have run this model more than a dozen times in the past nine months, with additional studies being scheduled regularly.

Más información

E0771 - Modelo singeneico de cáncer de mama

In this spotlight, we present data from our initial growth and efficacy studies with the E0771 model. The data presented here provides an overview of the E0771 cell line's response to immuno-oncology agents and radiation therapy to enable design of rational combination studies.

Más información

ID8: un modelo singeneico en ratones para la evaluación de inmunoterapias para el cáncer de ovario

ID8-Luc is a novel syngeneic mouse model developed to treat orthotopic ovarian cancer. Ovarian cancer remains a significant unmet medical need with a relative 5-year survival rate of 17 % in patients diagnosed with highly advanced stage IV ovarian cancer.

Más información


Un análisis más profundo de inmunofenotipo de linfocitos T infiltrantes

In this Tech Spotlight, we demonstrate the latter capability by presenting data generated using the new Expanded CompT™ panel, a 16-color panel that takes flow analysis of T cell activation and differentiation to a level above any other panel in the Covance service portfolio.
Más información

Conteo de valores absolutos por citometría de flujo: maximice la precisión de la interpretación de sus datos inmunofenotípicos

In this Tech Spotlight we will present the principles of absolute counting and the advantages this service provides when used in combination with tumor immunophenotypic analysis.
Más información

Análisis celular dendrítico integral por citometría de flujo a través del uso del nuevo panel CompDC™

To address the growing need for robust comprehensive DC immunophenotyping in murine pre-clinical models, Covance has configured a new standard panel, CompDC™. In this Tech Spotlight, we will demonstrate how various DC subsets in tumor and other tissue-derived cell samples can be analyzed using this panel.
Más información

Multiplexación de IHC para patrones de expresión, coexpresión y relaciones espaciales proteicas

Multiplex immunohistochemistry (IHC) is an assay that utilizes the basic concept of single antigen staining to detect multiple markers at one time. It allows for the labeling capabilities of peroxidase, alkaline phosphatase and other conjugated primary or secondary antibodies and can be achieved using several common methods including indirect or direct staining protocols.
Más información

Detección de fosfoproteínas en tumores sólidos a través de la citometría de flujo (phospho-flow)

In this article, we will be presenting phospho-protein detection in solid tumors using phospho-flow cytometry and reviewing the analysis of cabozantinib-induced inhibition of PI3K/AKT and JAK-STAT signaling in tumor vs. host immune cells.
Más información

Todos los artículos destacados >